Cargando…

The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study

INTRODUCTION: Brentuximab vedotin (BV) showed high overall remission rates in refractory/relapsed classical Hodgkin’s lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). Although the efficacy of BV has been reported in clinical trials, its efficacy as a frontline therapy in real world...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Xiaomeng, Guo, Wei, Wang, Yinping, Li, Jia, Zhao, Yangzhi, Qu, Limei, Yan, Xu, Li, Junna, Guo, Qiang, Young, Ken. H., Bai, Ou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799538/
https://www.ncbi.nlm.nih.gov/pubmed/34797505
http://dx.doi.org/10.1007/s12325-021-01943-z
_version_ 1784642083555901440
author Feng, Xiaomeng
Guo, Wei
Wang, Yinping
Li, Jia
Zhao, Yangzhi
Qu, Limei
Yan, Xu
Li, Junna
Guo, Qiang
Young, Ken. H.
Bai, Ou
author_facet Feng, Xiaomeng
Guo, Wei
Wang, Yinping
Li, Jia
Zhao, Yangzhi
Qu, Limei
Yan, Xu
Li, Junna
Guo, Qiang
Young, Ken. H.
Bai, Ou
author_sort Feng, Xiaomeng
collection PubMed
description INTRODUCTION: Brentuximab vedotin (BV) showed high overall remission rates in refractory/relapsed classical Hodgkin’s lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). Although the efficacy of BV has been reported in clinical trials, its efficacy as a frontline therapy in real world for patients with CD30 positive subtypes of non-Hodgkin’s lymphoma (NHL) such as peripheral T-cell lymphoma with T-follicular helper cell (TFH) phenotype (PTCL, TFH), anaplastic large-cell lymphoma (ALCL) and angioimmunoblastic T-cell lymphoma (AITL) in China has not been well documented. METHODS: Analysis of a real-world, observational, retrospective case series in patients suffering from AITL, sALCL and peripheral T-cell lymphoma with T-follicular helper phenotype (PTCL-TFH) and other types of PTCL treated with BV in frontline treatment was conducted. The patients were given treatment from May 2020 till June 28, 2021. All patients were pathologically diagnosed to have PTCL before treatment and expressed CD30. Patients received BV (1.8 mg/kg) combined with CEP (cyclophosphamide, epirubicin, prednisone acetate every 3 weeks). The primary endpoint was objective response rates (ORR), and secondary endpoints were duration of response and incidence of adverse events (AEs). Exploratory endpoints such as progression-free survival (PFS) are discussed even though after such a short period. RESULTS: Nineteen patients completed ≥ 1 cycles of BV-CEP treatment (16 cases completed ≥ 4 cycles, 3 cases only completed 1 cycle). Among them, the ORR reached 89.5% [CR 52.7%; partial response (PR) 36.8%]. In the ALCL group, CR reached 100% with the median duration of response of up to 8 months, while in the AITL group, the ORR was 75% and 2 patients had disease progression after treatment with BV + CEP. We also observed that BV-CEP may extend the PFS compared to traditional chemotherapy such as the CHOEP regimen (BV-CEP: not evaluable, CHOEP: 6.5 months), although the median follow-up was only 6.7 months. Adverse events (AEs), including incidence and severity of febrile neutropenia (26% patients in the BV-CEP group and 30% in the CHOEP group), were similar between groups. There was no incidence of AEs leading to treatment withdrawal or death under BV-CEP treatment. CONCLUSION: BV is a promising treatment in patients with ALCL, AITL and PTCL-TFH in frontline treatment settings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-021-01943-z.
format Online
Article
Text
id pubmed-8799538
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-87995382022-02-02 The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study Feng, Xiaomeng Guo, Wei Wang, Yinping Li, Jia Zhao, Yangzhi Qu, Limei Yan, Xu Li, Junna Guo, Qiang Young, Ken. H. Bai, Ou Adv Ther Original Research INTRODUCTION: Brentuximab vedotin (BV) showed high overall remission rates in refractory/relapsed classical Hodgkin’s lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). Although the efficacy of BV has been reported in clinical trials, its efficacy as a frontline therapy in real world for patients with CD30 positive subtypes of non-Hodgkin’s lymphoma (NHL) such as peripheral T-cell lymphoma with T-follicular helper cell (TFH) phenotype (PTCL, TFH), anaplastic large-cell lymphoma (ALCL) and angioimmunoblastic T-cell lymphoma (AITL) in China has not been well documented. METHODS: Analysis of a real-world, observational, retrospective case series in patients suffering from AITL, sALCL and peripheral T-cell lymphoma with T-follicular helper phenotype (PTCL-TFH) and other types of PTCL treated with BV in frontline treatment was conducted. The patients were given treatment from May 2020 till June 28, 2021. All patients were pathologically diagnosed to have PTCL before treatment and expressed CD30. Patients received BV (1.8 mg/kg) combined with CEP (cyclophosphamide, epirubicin, prednisone acetate every 3 weeks). The primary endpoint was objective response rates (ORR), and secondary endpoints were duration of response and incidence of adverse events (AEs). Exploratory endpoints such as progression-free survival (PFS) are discussed even though after such a short period. RESULTS: Nineteen patients completed ≥ 1 cycles of BV-CEP treatment (16 cases completed ≥ 4 cycles, 3 cases only completed 1 cycle). Among them, the ORR reached 89.5% [CR 52.7%; partial response (PR) 36.8%]. In the ALCL group, CR reached 100% with the median duration of response of up to 8 months, while in the AITL group, the ORR was 75% and 2 patients had disease progression after treatment with BV + CEP. We also observed that BV-CEP may extend the PFS compared to traditional chemotherapy such as the CHOEP regimen (BV-CEP: not evaluable, CHOEP: 6.5 months), although the median follow-up was only 6.7 months. Adverse events (AEs), including incidence and severity of febrile neutropenia (26% patients in the BV-CEP group and 30% in the CHOEP group), were similar between groups. There was no incidence of AEs leading to treatment withdrawal or death under BV-CEP treatment. CONCLUSION: BV is a promising treatment in patients with ALCL, AITL and PTCL-TFH in frontline treatment settings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-021-01943-z. Springer Healthcare 2021-11-19 2022 /pmc/articles/PMC8799538/ /pubmed/34797505 http://dx.doi.org/10.1007/s12325-021-01943-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Feng, Xiaomeng
Guo, Wei
Wang, Yinping
Li, Jia
Zhao, Yangzhi
Qu, Limei
Yan, Xu
Li, Junna
Guo, Qiang
Young, Ken. H.
Bai, Ou
The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study
title The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study
title_full The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study
title_fullStr The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study
title_full_unstemmed The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study
title_short The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study
title_sort short-term efficacy and safety of brentuximab vedotin plus cyclophosphamide, epirubicin and prednisone in untreated ptcl: a real-world, retrospective study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799538/
https://www.ncbi.nlm.nih.gov/pubmed/34797505
http://dx.doi.org/10.1007/s12325-021-01943-z
work_keys_str_mv AT fengxiaomeng theshorttermefficacyandsafetyofbrentuximabvedotinpluscyclophosphamideepirubicinandprednisoneinuntreatedptclarealworldretrospectivestudy
AT guowei theshorttermefficacyandsafetyofbrentuximabvedotinpluscyclophosphamideepirubicinandprednisoneinuntreatedptclarealworldretrospectivestudy
AT wangyinping theshorttermefficacyandsafetyofbrentuximabvedotinpluscyclophosphamideepirubicinandprednisoneinuntreatedptclarealworldretrospectivestudy
AT lijia theshorttermefficacyandsafetyofbrentuximabvedotinpluscyclophosphamideepirubicinandprednisoneinuntreatedptclarealworldretrospectivestudy
AT zhaoyangzhi theshorttermefficacyandsafetyofbrentuximabvedotinpluscyclophosphamideepirubicinandprednisoneinuntreatedptclarealworldretrospectivestudy
AT qulimei theshorttermefficacyandsafetyofbrentuximabvedotinpluscyclophosphamideepirubicinandprednisoneinuntreatedptclarealworldretrospectivestudy
AT yanxu theshorttermefficacyandsafetyofbrentuximabvedotinpluscyclophosphamideepirubicinandprednisoneinuntreatedptclarealworldretrospectivestudy
AT lijunna theshorttermefficacyandsafetyofbrentuximabvedotinpluscyclophosphamideepirubicinandprednisoneinuntreatedptclarealworldretrospectivestudy
AT guoqiang theshorttermefficacyandsafetyofbrentuximabvedotinpluscyclophosphamideepirubicinandprednisoneinuntreatedptclarealworldretrospectivestudy
AT youngkenh theshorttermefficacyandsafetyofbrentuximabvedotinpluscyclophosphamideepirubicinandprednisoneinuntreatedptclarealworldretrospectivestudy
AT baiou theshorttermefficacyandsafetyofbrentuximabvedotinpluscyclophosphamideepirubicinandprednisoneinuntreatedptclarealworldretrospectivestudy
AT fengxiaomeng shorttermefficacyandsafetyofbrentuximabvedotinpluscyclophosphamideepirubicinandprednisoneinuntreatedptclarealworldretrospectivestudy
AT guowei shorttermefficacyandsafetyofbrentuximabvedotinpluscyclophosphamideepirubicinandprednisoneinuntreatedptclarealworldretrospectivestudy
AT wangyinping shorttermefficacyandsafetyofbrentuximabvedotinpluscyclophosphamideepirubicinandprednisoneinuntreatedptclarealworldretrospectivestudy
AT lijia shorttermefficacyandsafetyofbrentuximabvedotinpluscyclophosphamideepirubicinandprednisoneinuntreatedptclarealworldretrospectivestudy
AT zhaoyangzhi shorttermefficacyandsafetyofbrentuximabvedotinpluscyclophosphamideepirubicinandprednisoneinuntreatedptclarealworldretrospectivestudy
AT qulimei shorttermefficacyandsafetyofbrentuximabvedotinpluscyclophosphamideepirubicinandprednisoneinuntreatedptclarealworldretrospectivestudy
AT yanxu shorttermefficacyandsafetyofbrentuximabvedotinpluscyclophosphamideepirubicinandprednisoneinuntreatedptclarealworldretrospectivestudy
AT lijunna shorttermefficacyandsafetyofbrentuximabvedotinpluscyclophosphamideepirubicinandprednisoneinuntreatedptclarealworldretrospectivestudy
AT guoqiang shorttermefficacyandsafetyofbrentuximabvedotinpluscyclophosphamideepirubicinandprednisoneinuntreatedptclarealworldretrospectivestudy
AT youngkenh shorttermefficacyandsafetyofbrentuximabvedotinpluscyclophosphamideepirubicinandprednisoneinuntreatedptclarealworldretrospectivestudy
AT baiou shorttermefficacyandsafetyofbrentuximabvedotinpluscyclophosphamideepirubicinandprednisoneinuntreatedptclarealworldretrospectivestudy